Clinical Trials Logo

Unresectable Solid Tumors clinical trials

View clinical trials related to Unresectable Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT04572451 Recruiting - Melanoma Clinical Trials

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Start date: November 29, 2021
Phase: Phase 1
Study type: Interventional

Nivolumab (and other agents affecting the anti-programmed death-1 [anti-PD-1] pathway) have demonstrated anti-tumor activity in multiple tumor types including non-small cell lung cancer (NSCLC), melanoma (MEL), renal cell carcinoma (RCC), and other cancers. However, there remains a large proportion of participants who do not achieve durable clinical benefit to nivolumab monotherapy. Combinations of immune-oncology (IO) agents with complimentary mechanisms as well as radiation represent a promising strategy to improve response rates to immunotherapy. In this phase I study, radiation will be used in combination with IO agents nivolumab and anti-IL-8 (BMS-986253) to assess toxicity by organ system. The study will determine the safe doses of radiation by organ site in conjunction with nivolumab and BMS-986253. The study will also provide the opportunity to evaluate changes in the tumor microenvironment induced by the treatment.